Company news
Nektar Therapeutics (NASDAQ:NKTR) news
Nektar Therapeutics news releases on 6ix. Latest, Oct 1, 2026: /UPDATE -- Nektar Therapeutics/
Press releases & updates
/UPDATE -- Nektar Therapeutics/
September 30, 2026
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
October 1, 2026
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
September 30, 2026
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
September 28, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
August 31, 2026
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
August 25, 2026
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
August 13, 2026
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
July 28, 2026
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
July 21, 2026
Nektar Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
Nektar Therapeutics Reports First Quarter 2026 Financial Results
May 7, 2026
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
April 28, 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
April 23, 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
April 20, 2026
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
April 20, 2026
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
April 19, 2026
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 27, 2026
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 19, 2026
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 11, 2026
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
February 25, 2026
Nektar Therapeutics to Participate in Two Investor Conferences in March
February 23, 2026
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
February 16, 2026
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
February 13, 2026
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
February 10, 2026
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
February 10, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
February 9, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2026
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
December 15, 2025
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
December 14, 2025
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
November 7, 2025
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
November 5, 2025
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
October 29, 2025
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
October 27, 2025
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
October 21, 2025
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
September 17, 2025
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
September 8, 2025
Nektar Therapeutics to Participate in Two Investor Conferences in September
September 2, 2025
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
August 6, 2025
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
July 30, 2025
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
July 1, 2025
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
June 30, 2025
Nektar Therapeutics Announces Proposed Public Offering
June 29, 2025
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
June 23, 2025
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
June 22, 2025
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 12, 2025
Nektar Therapeutics Reports First Quarter 2025 Financial Results
May 7, 2025
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
April 30, 2025
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2025
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025